European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - eptifibatide - angina, unstable; myocardial infarction - antithrombotic agents - integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ecg changes and / or elevated cardiac enzymes.patients most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (ptca).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - eptifibatide, quantity: 0.75 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; citric acid monohydrate - integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials). indications as at 29 november 2001: integrilin is indicated for patients undergoing nonurgent percutaneous coronary intervention with intracoronary stenting (see clinical trials). integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - eptifibatide, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; citric acid monohydrate; sodium hydroxide - integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials). indications as at 29 november 2001: integrilin is indicated for patients undergoing nonurgent percutaneous coronary intervention with intracoronary stenting (see clinical trials). integrilin is indicated for the treatment of patients with unstable angina or non-q-wave myocardial infarction (see clinical trials).

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 0.75 mg in 1 ml - integrilin® is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). integrilin is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with integrilin is contraindicated in patients with: - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke - current or planned administratio

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 2 mg in 1 ml - integrilin® is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). integrilin is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with integrilin is contraindicated in patients with: - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke - current or planned administratio

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - eptifibatide (unii: na8320j834) (eptifibatide - unii:na8320j834) - eptifibatide 2 mg in 1 ml - integrilin® is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (mi) in patients with acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (pci). integrilin is indicated to decrease the rate of a combined endpoint of death, new mi, or need for urgent intervention in patients undergoing pci, including those undergoing intracoronary stenting [see clinical studies (14.1, 14.2)] . treatment with integrilin is contraindicated in patients with: - a history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days - severe hypertension (systolic blood pressure >200 mm hg or diastolic blood pressure >110 mm hg) not adequately controlled on antihypertensive therapy - major surgery within the preceding 6 weeks - history of stroke within 30 days or any history of hemorrhagic stroke - current or planned administratio

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - solution for infusion - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - solution for injection - eptifibatide 2 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

United States - English - NLM (National Library of Medicine)

integrity made llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - do not use - for children less than 2 months of age - on open skin wounds uses: handsanitizer to help reduce bacteria that potentially can cause disease. for use when soap and wateer are not available stop use and ask a doctor if - irritation or rash occurs - condition persists for more than 72 hours

United States - English - NLM (National Library of Medicine)

integrity made llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - do not use - for children less than 2 months of age - on open skin wounds uses: handsanitizer to help reduce bacteria that potentially can cause disease. for use when soap and wateer are not available stop use and ask a doctor if - irritation or rash occurs - condition persists for more than 72 hours